Court of Appeals Affirms No Infringement

    PITTSBURGH, June 10 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL)
announced today that the U.S. Court of Appeals for the Federal Circuit has
affirmed a May 2007 District Court ruling stating that Mylan's 10 mg and 20 mg
Omeprazole delayed-release capsules do not infringe patents asserted against
Mylan by AstraZeneca. Omeprazole is the generic version of AstraZeneca LP's
Prilosec(R).
    Mylan launched its Omeprazole products on August 4, 2003, despite the
patent infringement litigation, which at the time was unprecedented in the
generic pharmaceutical industry.
    "Once again, we are pleased to have prevailed in court, and we believe
that this decision ends the patent litigation surrounding this product for our
company," said Mylan Vice Chairman and CEO Robert J. Coury. "Our original
decision to launch this product means that consumers, the government and
third-party payors have benefited significantly for nearly five years because
they've had access to a lower-cost generic version of Prilosec."
    Mylan Inc., with a presence in more than 90 countries, ranks among the
leading diversified generic and specialty pharmaceutical companies in the
world. The company maintains one of the industry's broadest -- and highest
quality -- product portfolios, supported by a robust product pipeline; owns a
controlling interest in the world's second largest active pharmaceutical
ingredient manufacturer; and operates a specialty business focused on
respiratory and allergy therapies.

SOURCE Mylan Inc. -0- 06/10/2008 /CONTACT: Media, Michael Laffin, or Investors, Kris King, of Mylan Inc., +1-724-514-1813/ /Web site: http://www.mylan.com / (MYL)

CO: Mylan Inc. ST: Pennsylvania IN: HEA MTC SU: LAW

BP-CS -- NETU114 -- 0482 06/10/2008 15:15 EDT http://www.prnewswire.com